Cingulate Inc (CING) - Net Assets
Based on the latest financial reports, Cingulate Inc (CING) has net assets worth $2.51 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.07 Million) and total liabilities ($12.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cingulate Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.51 Million |
| % of Total Assets | 16.64% |
| Annual Growth Rate | 26.37% |
| 5-Year Change | -87.96% |
| 10-Year Change | N/A |
| Growth Volatility | 648.25 |
Cingulate Inc - Net Assets Trend (2019–2025)
This chart illustrates how Cingulate Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Cingulate Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cingulate Inc (2019–2025)
The table below shows the annual net assets of Cingulate Inc from 2019 to 2025. For live valuation and market cap data, see Cingulate Inc (CING) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.51 Million | -66.35% |
| 2024-12-31 | $7.46 Million | +208.53% |
| 2023-12-31 | $-6.87 Million | -276.95% |
| 2022-12-31 | $3.88 Million | -81.38% |
| 2021-12-31 | $20.84 Million | +1512.73% |
| 2020-12-31 | $1.29 Million | +109.85% |
| 2019-12-31 | $615.88K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cingulate Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13237503100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $725.00 | 0.03% |
| Other Components | $134.88 Million | 5376.17% |
| Total Equity | $2.51 Million | 100.00% |
Cingulate Inc Competitors by Market Cap
The table below lists competitors of Cingulate Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Norcod As
OL:NCOD
|
$62.76 Million |
|
Campina Ice Cream Industry Tbk PT
JK:CAMP
|
$62.76 Million |
|
Ways Technical Ltd
TWO:3508
|
$62.77 Million |
|
Maat Pharma SA
PA:MAAT
|
$62.81 Million |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
$62.69 Million |
|
Dongyang Expre
KO:084670
|
$62.68 Million |
|
Oriental Food Industries Hold
KLSE:7107
|
$62.67 Million |
|
Herige SA
PA:ALHRG
|
$62.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cingulate Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,455,505 to 2,508,907, a change of -4,946,598 (-66.3%).
- Net loss of 22,450,000 reduced equity.
- New share issuances of 10,153,812 increased equity.
- Other factors increased equity by 7,349,590.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.45 Million | -894.81% |
| Share Issuances | $10.15 Million | +404.71% |
| Other Changes | $7.35 Million | +292.94% |
| Total Change | $- | -66.35% |
Book Value vs Market Value Analysis
This analysis compares Cingulate Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.75x to 11.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.44 | $5.12 | x |
| 2020-12-31 | $0.91 | $5.12 | x |
| 2021-12-31 | $14.74 | $5.12 | x |
| 2022-12-31 | $2.75 | $5.12 | x |
| 2023-12-31 | $-3.04 | $5.12 | x |
| 2024-12-31 | $1.96 | $5.12 | x |
| 2025-12-31 | $0.46 | $5.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cingulate Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -894.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.01x
- Recent ROE (-894.81%) is below the historical average (-584.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -1874.76% | 0.00% | 0.00x | 8.57x | $-11.61 Million |
| 2020 | -555.82% | 0.00% | 0.00x | 4.48x | $-7.31 Million |
| 2021 | -99.51% | 0.00% | 0.00x | 1.10x | $-22.82 Million |
| 2022 | -459.82% | 0.00% | 0.00x | 2.94x | $-18.24 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.85 Million |
| 2024 | -208.51% | 0.00% | 0.00x | 1.99x | $-16.29 Million |
| 2025 | -894.81% | 0.00% | 0.00x | 6.01x | $-22.70 Million |
Industry Comparison
This section compares Cingulate Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cingulate Inc (CING) | $2.51 Million | -1874.76% | 5.01x | $62.72 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more